Recursion Pharmaceuticals Inc (RXRX) FY2025Q4 Earning Prediction
Recursion Pharmaceuticals Inc (RXRX) is set to release its FY2025Q4 earnings performance on 02/25 06:30:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 21.22M and an earnings per share (EPS) of -0.28 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
RXRX Transcript
The earnings call highlights strong financial management, with a robust cash position and significant partnership inflows, particularly from Roche and Genentech. The company has reduced expenses by 35% and has a clear runway through 2027 without additional financing. The Q&A session revealed positive analyst sentiment, with management providing detailed and clear responses. The focus on AI-driven platform development and the strategic partnerships with major players like Sanofi and Roche further bolster confidence. Given these factors, the stock is likely to see a positive movement over the next two weeks.
RXRX Report
Frequently Asked Questions
What is the Recursion Pharmaceuticals Inc FY2025Q4 Earnings Release Date and Time?
Recursion Pharmaceuticals Inc (RXRX) is scheduled to release its FY2025Q4 earnings report on Feb 25, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Recursion Pharmaceuticals Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 21.22M in revenue and an EPS of -0.28 for Recursion Pharmaceuticals Inc's FY2025Q4.
What Does Intellectia's AI Predict for Recursion Pharmaceuticals Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for Recursion Pharmaceuticals Inc's FY2025Q4 earnings, with a prediction date of Feb 25, 2026. Recursion Pharmaceuticals Inc {summary}
How Can I Use This Earnings Prediction to Trade RXRX Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Feb 25, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Recursion Pharmaceuticals Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
